Reply: The Need for Prudence When Using 18F-FDG PET as a Reference Standard for Lymphoma Detection

Sue C. Kaste; Monika Metzger; Barry L. Shulkin

doi:10.2967/jnumed.117.190652

REPLY: Thank you for allowing us to respond to Drs. Adams and Kwee, who caution readers about the utility of ¹⁸F-FDG in this letter, as they have done in many others (1–6). We thank them for their comments on our article (7) and appreciate their perspective on ¹⁸F-FDG, which, though imperfect, remains internationally regarded as the functional imaging agent of choice for patients with lymphoma.

Footnotes

Published online Apr. 27, 2017.

REFERENCES

1.↵
1. Adams HJ,
2. Kwee TC
. Interim PET-CT scan in advanced Hodgkin’s lymphoma [letter]. N Engl J Med. 2016;375:999.
OpenUrl
2.
1. Adams HJ,
2. Kwee TC
. A negative ¹⁸F-FDG-PET scan can never exclude residual disease [letter]. Nucl Med Commun. 2016;37:102–103.
OpenUrl
3.
1. Adams HJ,
2. Kwee TC
. Prevention of large-scale implementation of unnecessary and expensive predictive tests in Hodgkin’s lymphoma [letter]. Lancet Haematol. 2017;4:e63–e64.
OpenUrl
4.
1. Adams HJA,
2. Kwee TC
. Do not abandon the bone marrow biopsy yet in diffuse large B-cell lymphoma [letter]. J Clin Oncol. 2015;33:1217–1218.
OpenUrl FREE Full Text
5.
1. Adams HJA,
2. Kwee TC
. In regard to Ceriani et al. [letter]. Int J Radiat Oncol Biol Phys. 2017;97:869–870.
OpenUrl
6.↵
1. Adams HJ,
2. Kwee TC
. Neither posttreatment PET/CT nor interim PET/CT using Deauville criteria predicts outcome in pediatric Hodgkin lymphoma [letter]. J Nucl Med. 2017;58:684–685.
OpenUrl FREE Full Text
7.↵
1. Kaste SC,
2. Snyder SE,
3. Metzger ML,
4. et al
. Comparison of ¹¹C-methionine and ¹⁸F-FDG PET/CT for staging and follow-up of pediatric lymphoma. J Nucl Med. 2017;58:419–424.
OpenUrl Abstract/FREE Full Text